Allylescaline

Allylescaline (3,5-dimethoxy-4-allyloxyamphetamine, commonly abbreviated ALS) is a psychedelic phenethylamine and structural analog of mescaline, in which the 4-methoxy group of mescaline is replaced with a 4-allyloxy group — an oxygen-linked allyl (prop-2-en-1-yl) chain. It is one of several mescaline analogs synthesized and characterized by Alexander Shulgin, documented in PiHKAL (1991) as part of his extensive exploration of trimethoxyphenethylamine structure-activity relationships.

At active doses (20–60 mg), allylescaline produces a psychedelic experience lasting 8–12 hours, broadly similar in character to mescaline but with significantly higher potency by weight — requiring a fraction of the dose needed for the parent compound. The experience is characterized by rich visual phenomena, sensory enhancement, emotional opening, and — in many accounts — a warm, empathogenic quality that community members describe as reminiscent of the more entactogenic phenethylamines. This character may reflect allylescaline's specific receptor engagement profile, which may differ from mescaline in ways that bias the experience toward emotional versus purely perceptual effects.

As a Shulgin phenethylamine with moderate community use, allylescaline occupies a well-defined niche among experienced psychedelic explorers interested in the mescaline analog space. Its legal status is complex — it is not always explicitly scheduled but is subject to analogue acts in many jurisdictions. Limited formal safety data means that the community experience base, while substantial, represents the primary source of harm reduction information.